N-[2-(4-Methoxycarbonylphenoxy)ethyl]phthalimide | 113459-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-[2-(4-Methoxycarbonylphenoxy)ethyl]phthalimide
• 英文别名: methyl 4-(2-phthalimidoethyloxy)benzoate；methyl 4-[2-(1,3-dioxoisoindolin-2-yl)ethoxy]benzoate；Methyl 4-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)benzoate；methyl 4-[2-(1,3-dioxoisoindol-2-yl)ethoxy]benzoate
• CAS: 113459-58-8
• 化学式: C₁₈H₁₅NO₅
• 分子量: 325.321
• InChiKey: GLEZCEZHHPBIQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[2-(4-Methoxycarbonylphenoxy)ethyl]phthalimide 在 肼 作用下， 以 甲醇 为溶剂， 反应 20.0h， 生成 4-(2-氨基乙氧基)苯甲酸甲酯
  参考文献：
  名称：

  Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist

  摘要：

  Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.

  DOI：

  10.1021/jm000133v
• 作为产物：
  描述：

  甲基-4-(2-溴乙氧基)苯甲酸 、 potassium phtalimide 以 N,N-二甲基甲酰胺 为溶剂， 以94%的产率得到N-[2-(4-Methoxycarbonylphenoxy)ethyl]phthalimide
  参考文献：
  名称：

  Benzoic acid derivatives

  摘要：

  式(I)的化合物##STR1##或其药用盐，其中R.sup.1是氢、卤素或烷基，R.sup.2是氢或烷基，可用于降低动物（包括人类）的血清脂质。

  公开号：

  US04831055A1

文献信息

• Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated
  申请人：Merck & Co., Inc.

  公开号：US05741796A1

  公开（公告）日：1998-04-21

  Compounds of the following general structure X-Y-Z-Aryl-A-B, for example, ##STR1## which inhibit osteoclast mediated bone resorption. Specifically, the compounds are useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy. The compounds may be administered in oral dosage forms such as tablets, capsules, e.g. sustained release capsules, powders, granules, and suspensions.

  以下具有一般结构X-Y-Z-Aryl-A-B的化合物，例如##STR1##，可以抑制破骨细胞介导的骨吸收。具体而言，这些化合物可用于治疗因骨吸收增加引起或介导的骨病症状的哺乳动物，需要此类治疗。这些化合物可以以口服剂量形式给予，例如片剂、胶囊，例如持续释放胶囊，粉末，颗粒和悬浮液。
• Guainidino, formamidino, amino and related compounds for inhibiting
  申请人：Merck & Co., Inc.

  公开号：US05929120A1

  公开（公告）日：1999-07-27

  Compounds of the following general structure X--Y--Z-Aryl-A--B, ##STR1## which inhibit osteoclast mediated bone resorption.

  下列一般结构为X--Y--Z-Aryl-A--B的化合物，可以抑制破骨细胞介导的骨吸收。##STR1##
• Synthesis and activities of new arylsulfonamido thromboxane A2 receptor antagonists
  作者：E Sartori、F Camy、JM Teulon、F Caussade、A Virone-Oddos、A Cloarec

  DOI：10.1016/0223-5234(93)90093-t

  日期：1993.1

  New benzoic, benzeneacetic and thiazole-4-acetic acids bearing an arylsulfonamido alkyl or alkylhetero side chain were synthesized and tested in vitro for affinity for human platelet thromboxane A2 receptors and inhibition of U46619-induced rat aortic ring contraction. Influence of substitution patterns, chain length and presence of heteroatoms were studied and compounds within a 30 nmol range for inhibition of U46619-induced contractions were found. One of the most potent, 2-[(4-chloro-benzenesulfonylamino-ethyl)thio] thiazole-4-acetic acid (VII-4) was orally active (1 mg/kg), as evidenced by the inhibition of U46619-induced platelet aggregation in guinea pigs, ex vivo.
• YOSHIKUNI, YOSHIAKI;CHOKAI, SHOICHI;OZAKI, TAKAYUKI;YOSHIDA, HIROTSUGU;TA+
  作者：YOSHIKUNI, YOSHIAKI、CHOKAI, SHOICHI、OZAKI, TAKAYUKI、YOSHIDA, HIROTSUGU、TA+

  DOI：——

  日期：——
• COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION
  申请人：Merck & Co., Inc.

  公开号：EP0760658A1

  公开（公告）日：1997-03-12